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Abstract
Background Although a few studies have been reported on
predictive factors of postoperative diabetes remission, the
conclusions remain inconsistent. This meta-analysis aimed
to assess the preoperative clinical factors for type 2 diabetes
mellitus (T2DM) remission after bariatric surgery.
Methods The Cochrane Library, PubMed, MEDLINE,
Embase, and CINAHL databases were searched. All human
studies published in English between 1 January 1992 and 1
September 2013 reporting on the parameters of interest were
included.
Results In total, 15 studies involving 1,753 bariatric surgery
patients were selected. Analyses were performed separately
for the parameters of interest. T2DM remission was observed
to be negatively correlated with age, diabetes duration, insulin
use, and HbA1c levels. Baseline body mass index (BMI) and
C-peptide levels were positively associated with the remission
rate in Asian patients. However, there was no significant
association between gender and remission rate.
Conclusions Patients with younger age, short diabetes dura-
tion, better glucose control, and better β cell function were
more likely to achieve T2DM remission after bariatric surgery.
However, further randomized controlled trials with uniform
remission criteria should be conducted to provide more reli-
able evidence.
Keywords Type 2 diabetes . Diabetes remission .
Bariatric surgery . Metabolic surgery
Introduction
It is generally accepted that obese patients with type 2 diabetes
mellitus (T2DM) achieve significant and lasting weight loss
and T2DM remission after bariatric surgery [1–4]. This re-
markable effect can minimize the possibility of future com-
plications, particularly the risk of cardiovascular disease.
However, bariatric procedures may be irreversible and asso-
ciated with considerable short- and long-term risks. Moreover,
although most patients achieve a marked improvement in
T2DM, not every patient achieves remission after surgery,
and in some, substantial improvement is not observed.
Optimal outcomes of surgical treatment for diabetes can be
obtained only if the most appropriate patients best suited for
bariatric surgery are selected. Even more important is the
identification of patients who do not respond well to bariatric
surgery. Previous studies have identified many preoperative
patient factors associated with surgical outcomes, including
age, diabetes duration, glycemic control (HbA1c), fasting C-
peptide levels, body mass index (BMI), ethnicity, and
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medications used to manage blood glucose (including
oral hypoglycemic agents and insulin). However, the
conclusions of these studies are inconsistent. Against
this background, the primary aim of this meta-analysis
was to identify the preoperative predictors of diabetes
remission. After reviewing relevant articles, we focused
on the following parameters: age, gender, diabetes du-
ration, insulin use, baseline BMI, and levels of fasting
glucose, HbA1c, and C-peptide. Our findings provide
important implications for the identification of patients
most likely to benefit from bariatric surgery.
Materials and Methods
Search Strategy and Article Selection
The Preferred Reporting Items for Systematic Reviews and
Meta-Analyses 2009 Guidelines (PRISMA) were used to
conduct data extraction [5]. We conducted a comprehensive
review of all studies published in the English literature con-
taining the parameters of interest and T2DM remission with




CINAHL (http://www.ebscohost.com) databases were
searched for articles published from 1 January 1992 through
1 September 2013, with the following search terms:
“diabetes* [All Fields],” “surg* [All Fields],” “operat* [All
Fields],” (“diabetes mellitus” [MeSH Terms] OR “diabetes”
[All Fields] AND “mellitus” [All Fields]) OR “diabetes
mellitus” [All Fields] OR “diabetes” [All Fields] and
“remission* [All Fields],” or “improve* [All Fields].”
Further searches were performed by reviewing abstract
booklets and review articles. Relevant articles referenced in
these publications were downloaded from the databases and
used to widen the search results.
Selection of Studies
Two reviewers (G.F.W. and Y.X.Y.) independently
screened the retrieved articles. All clinical studies
reporting on the parameters of interest and T2DM re-
mission were selected and assessed independently and
then cross-checked. T2DM remission was defined as
cessation of glucose-lowering medications, and it was
grouped according to specific HbA1c thresholds. There
were no restrictions regarding the surgical procedure.
All qualifying articles were then reviewed to verify that
each contained sufficient data for analysis, including
continuous data reported as means with standard devia-
tions and sample size and dichotomous data reported as
a number with sample size. Case reports, conference
abstracts, review articles, and non-human studies were
excluded. Studies with the same or overlapping cohort
of patients were identified as “kinned,” and the largest
dataset was chosen from those studies and counted only
once.
Data Extraction
Two reviewers (Y.X.Y. and G.F.W.) independently extracted
data, and disagreements were resolved through discussion
before analysis. Any unresolved disagreement was judged
by the third investigator. Details extracted from the studies
included the following: first author, publication year, country,
ethnicity, study setting, time frame, study design, sample size,
patient age, gender composition, duration of T2DM history,
baseline BMI, fasting glucose levels, C-peptide and HbA1c
levels, insulin use, type of surgical procedure performed, and
definition used for remission. We did not contact authors for
unreported data.
Assessment of Methodological Quality
Two reviewers (Y.X.Y. and G.F.W.) independently assessed
the quality risk of bias in each included study using the
Newcastle–Ottawa Scale, which was developed to assess the
quality of non-randomized studies [6]. The scale awards a
maximum of nine points. Studies of high quality received a
score of the maximum nine points, studies of medium quality
scored seven to eight points, and studies of low quality scored
less than seven points [7].
Statistical Analysis
RevMan 5.0 software (Cochrane Collaboration; http://www.
cochrane.org/) was used for statistical analysis of the data. We
summarized the available data from all trials reporting results.
For results of continuous outcomes, weighted mean
differences (WMDs) and standard deviations were assessed.
However, for dichotomous outcomes, risk ratios were used to
calculate the case results using odds ratios (ORs) and 95 %
confidence intervals (CIs). Significant heterogeneity was in-
dicated by a probability (P) value of <0.1 or heterogeneity
(H2) value of >50 %. A random effects model was used if
there was a significant heterogeneity; if not, a fixed effects
model was used. For heterogeneous studies in the meta-anal-
ysis, the results were cautiously interpreted. Publication bias
was evaluated by constructing funnel plots with visual assess-
ment of asymmetry. Using the “trim and fill” method to
identify and correct for funnel plot asymmetry arising from
publication bias, pooled effect estimates were recalculated for
each analysis.
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Results
Characteristics of Eligible Studies
A total of 877 publications were identified through searching
the literature databases and cited references. Of these, 732
were excluded because of the lack of relevance to diabetes
remission or improvement. After further evaluation, we ex-
cluded an additional 128 studies because of insufficient data,
abstract only, review article, or overlapping data with another
study. Finally, 15 studies were selected. A flow diagram
outlining the systematic review process is presented in Fig. 1.
The 15 eligible articles included a total of 1,753 T2DM
patients [8–22]. Most studies were conducted in the USA
(seven), with the others conducted in Brazil (one), Taiwan
(one), Italy (one), Korea (one), China (one), Spain (two), and
New Zealand (one). Of these 15 studies, nine were retrospec-
tive, five were prospective, and one was an observational
study. The study participants generally had poor glycemic
control. Laparoscopic Roux-en-Y gastric bypass (LRYGB)
was performed in 4 studies, RYGB was performed in 10
studies, and laparoscopic sleeve gastrectomy (LSG) was per-
formed in 2 study. The follow-up interval ranged from 6 to
36 months, with the most frequently reported interval being
12 months. The setting for the studies was most commonly an
academic hospital, with one study each in a community hos-
pital and private practice. The majority of the included studies
were considered of good quality by our assessment criteria
(score of ≥7). The characteristics of the included articles are
presented in Table 1.
Patient Characteristics
The mean patient age at baseline varied among the studies and
ranged from 33 to 54 years. The mean BMI at baseline ranged
from 26.9 to 51.6 kg/m2. Resolution of T2DM was defined
and reported in a variety of ways (HbA1c levels of <5–6, 5.7,
6.5, and 7.0 %) without glucose-lowering therapy. The
Original search of electronic databases: 877 articles 
(PubMed, 735; MEDLINE, 120; CINAHL, 22)
732 articles excluded because of lack of relevance of the topic 
or the same articles retrieved from multiple databases
145 potentially relevant articles
86 articles excluded:
15 rats
17 conferences and abstracts
14 reviews
4 case reports 
14 comments or letters 
22 not related to diabetes remission or improvement
59 acceptable for further review
43 articles excluded: 
7 data overlapping with another study
32 insufficient data
3 no comparison between remission and no remission
(1: good outcome vs. bad outcome;
1: improvement vs. no improvement; 
1: un-responders vs. improved or/remission)
2 Involved gastric restriction
15 studies included (age: 13; BMI: 13; C-peptide: 2; diabetes 
duration: 13; FPG: 9; HbA1c: 13; gender: 13; insulin users: 10)
Fig. 1 Selection of articles for
inclusion in meta-analysis
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patient characteristics of the included articles are pre-
sented in Table 2.
Quantitative Synthesis Meta-Analysis
BMI
A total of 1,149 T2DM patients in 13 studies were included in
the meta-analysis to identify the correlation between preoper-
ative BMI and T2DM remission [8–14, 16, 17, 19–22]. Of
these, seven studies were conducted in North America, one in
South America, three in Asia, one in Oceania, and one in
Europe. Our meta-analysis showed no significant association
between baseline BMI and T2DM remission (random model,
OR=0.45, 95 % CI=1.40 to 2.31, P=0.63). Stratified analysis
demonstrated significant differences associated with Asian
ethnicity (random model, OR=2.09, 95 % CI=1.06 to 3.13,
P<0.01), although there was still no statistical significance
between baseline BMI and non-Asian ethnicity. Thus, Asian
T2DM patients with higher baseline BMI scores may have a
higher propensity for postoperative remission.
Patient Age
A total of 1,149 T2DM patients in 13 studies were included in
the meta-analysis of the relationship between preoperative age
and T2DM remission [8–14, 16, 17, 19–22]. Of these, seven
studies were conducted in North America, one in South
America, three in Asia, one in Oceania, and one in Europe.
The results of the meta-analysis showed a negatively signifi-
cant association between baseline age and T2DM remission
(random model, OR=−2.46, 95 % CI=−3.90 to −1.02,
P<0.01), even with stratified analysis by ethnicity. No publi-
cation bias was detected by funnel plot analysis (data not
shown). Thus, younger T2DM patients may have a higher
remission rate.
Duration of Diabetes
A total of 1,555 T2DM patients in 13 studies were included in
the meta-analysis of the relationship between diabetes dura-
tion and T2DM remission [8–14, 16–21]. Of these, seven
studies were conducted in North America, two in Asia, one
in Oceania, and three in Europe. The meta-analysis results
showed a significant association between diabetes duration
and T2DM remission (random model, OR=−5.22, 95 % CI=
−7.39 to −3.42, P<0.01), even with stratified analysis by
ethnicity. No publication bias was detected by funnel plot
analysis (data not shown). Thus, T2DM patients with short
diabetes duration may have a higher remission rate.
Fasting Glucose Levels
A total of 914 T2DM patients in nine studies were included in
the meta-analysis of the relationship between preoperative
fasting glucose levels and T2DM remission [8–12, 14, 16,
19, 22]. Of these, three studies were conducted in North
America, three in Asia, one in Oceania, and two in Europe.
The meta-analysis results showed a significant association
between baseline fasting glucose levels and T2DM remission
(random model, OR=−19.95, 95 % CI=−31.85 to −8.05,
P<0.01). However, there was no relationship between fasting
glucose levels and diabetes remission after stratified analysis
by ethnicity (fixed model, OR=−15.16, 95 % CI=−38.58 to
8.27, P=0.20). Publication bias was detected in non-Asian
studies by funnel plot analysis (data not shown). Thus, T2DM
patients with increased baseline fasting glucose levels may
have a lower remission rate in non-Asian patients.
HbA1c Levels
A total of 1,149 T2DM patients in 13 studies were included in
the meta-analysis of the relationship between preoperative
HbA1c levels and T2DM remission [8–14, 16, 17, 19–22].
Of these, seven studies were conducted in North America, one
in South America, three in Asia, one in Oceania, and one in
Europe. The meta-analysis results showed a significant asso-
ciation between baseline HbA1c levels and T2DM remission
(random model, OR=−0.80, 95 % CI=−1.20 to −0.41,
P<0.01) (Fig. 2), even with stratified analysis by ethnicity.
No publication bias was detected by funnel plot analysis (data
not shown). Thus, T2DM patients with increased baseline
HbA1c levels may have a lower remission rate.
C-peptide Levels
A total of 149 T2DM patients in two Asian studies were
included in the meta-analysis of the relationship between
baseline C-peptide levels and T2DM remission [16, 22]. Our
meta-analysis showed a significant association between base-
line C-peptide levels and T2DM remission (random model,
OR=0.62, 95 % CI=0.33 to 0.91, P<0.01). No publication
bias was detected by funnel plot analysis (data not shown).
Thus, T2DM patients with higher C-peptide levels may have a
higher remission rate among Asians.
Insulin Use
A total of 1,350 T2DM patients in 10 studies were included in
the meta-analysis of the relationship between insulin use and
T2DM remission [8, 9, 11, 13, 14, 16, 18–21]. Of these, six
studies were conducted in the USA, two in Asia, and two in
Europe. The meta-analysis results showed a significant asso-
ciation between insulin use and T2DM remission (random
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model, OR=0.15, 95 % CI=0.11 to 0.20, P<0.01), even with
stratified analysis by ethnicity. No publication bias was de-
tected by funnel plot analysis (data not shown). Thus, non-
Asian patients on insulin therapy before surgery may have a
lower remission rate.
Gender
A total of 1,113 T2DM patients in 13 studies were included in
the meta-analysis of the relationship between gender and
T2DM remission [8, 10, 11, 13–17, 19–22]. Of these, seven
studies were conducted in the USA, three in Asia, one in
Oceania, and two in Europe. The meta-analysis results
showed an insignificant association between gender and
T2DM remission. No publication bias was detected by funnel
plot analysis (data not shown). Thus, gender may not be a
predictor of T2DM remission after bariatric surgery.
Publication Bias and Heterogeneity Analyses
The funnel plots were inspected for underlying geometric
distribution and were found to be symmetrical inmost models.
No publication bias was detected in the funnel plots using
Begg’s method with the exception of fasting glucose levels,
suggesting the absence of publication bias in most meta-
analysis models. Similarly, significant heterogeneity was ob-
served in most models. To investigate this further, we per-
formed meta-regression analysis to identify the source of
heterogeneity using the criteria of publication year, ratio of
males, sample size, T2DM remission criterion, and quality
scoring. Univariate meta-regression analysis revealed that
none of the tested covariates could explain the observed
differences in heterogeneity between the studies. Moreover,
when the data were stratified by ethnicity, heterogeneity was
not significantly decreased or eliminated.
Fig. 2 Forest plot of comparison:
remission vs no remission in
terms of baseline HbA1c. Mean
differences are shown with 95 %
CIs. a–c For HbA1c. a For all
included studies, b studies from
North America, c studies from
Asian
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Sensitivity Analysis
Sensitivity analysis was performed to assess the influence of
each individual study on the pooled OR values by sequentially
repeating the meta-analysis excluding one study at a time. The
results of this analysis suggested that the pooled OR values
were not significantly affected (data not shown), indicating
statistically robust results.
Discussion
Complementing previous comprehensive studies, our meta-
analysis provides additional results for the identification of
potential predictors of diabetes remission after bariatric sur-
gery by stratifying patients according to ethnicity. The major
findings of our analysis are that for both Asian and non-Asian
obese T2DM patients, older age, long history of diabetes,
insulin use, and poor glycemic control can be assumed to be
negative predictors for failure of diabetes remission in the
postoperative course. Moreover, our results indicated that
gender and baseline BMI do not play a role in diabetes
remission. In addition, Asian T2DM patients appeared to have
a better remission rate of diabetes after bariatric surgery, which
was also correlated with lower severity of T2DM.
Previous observational studies suggested age, shorter dis-
ease duration, and appropriate glycemic control prior to sur-
gery as predictors of disease remission [23–32]. The results of
our meta-analysis further confirmed these findings. Thus, age,
diabetes duration, and appropriate glycemic control appear to
be selective criteria among Asian and non-Asian patients.
Furthermore, we confirmed that disease severity is an
important predictive factor of the extent of improvement that
can be potentially achieved after bariatric surgery, particularly
for Asian patients. High level of HbA1c is widely considered
as a marker for uncontrolled T2DM. It is a common practice
among many surgical teams to exclude patients from surgical
treatment or at least to postpone further scheduled operation
due to a high level of HbA1c. Although there is no consensus
regarding not operating these patients, the assumption that
patients with higher HbA1c are at greater risks of periopera-
tive morbidity and mortality is probably extrapolated from
bariatric procedures. The selection of which patients should
not be operated due to advanced or severe uncontrolled T2DM
may be one of the reasons why the difference between the
T2DM remission and non-remission group is not much larger.
The results of our meta-analysis also confirmed that the higher
HbA1c is negatively associated with the T2DM remission, the
further a study should explore the HbA1c cutoff setting. On
the other hand, previous studies have shown that relatively
less deterioration of β cell function at the time of surgery may
maximize the effect of surgery to increase β cell insulin
secretion [28]. In contrast, a worse initial degree of β cell
dysfunction may lower the chances of T2DM remission [20].
Therefore, preoperative assessment of insulin secretion capac-
ity could be proven useful to grade the stage and severity of
T2DM and to predict the diabetes status after RYGB surgery.
Measurement of fasting C-peptide levels is a commonly ac-
cepted method to assess insulin secretion [33, 34], which is
often used to estimate disease severity. Improvement in C-
peptide levels has been confirmed to significantly reduce the
probability of diabetes remission [35, 36]. The results of our
meta-analysis showing that T2DM patients with higher C-
peptide levels achieved a better remission rate support this
viewpoint. However, there were no available data to appro-
priately analyze the relationship between C-peptide and
T2DM remission in non-Asian patients. Therefore, further
studies are needed to confirm a possible correlation among
other ethnic groups.
Interestingly, our meta-analysis yielded some unexpected
and provocative results regarding the association between
BMI and diabetes remission. As is well known, an increase
in BMI is closely related to protracted insulin resistance [37].
The main mechanism of T2DM remission after bariatric sur-
gery is the amelioration of insulin resistance; therefore, a high
BMI may hold predictive value for the success of metabolic
surgery for T2DM [38–40]. However, in our meta-analysis,
we found that a high BMI may be predictive of the success of
metabolic surgery for T2DM only in Asian patients.
Therefore, it remains uncertain whether BMI is a predictive
factor in non-Asian patients. We believe that our non-
significant result may have been due to the inclusion of
non-Asian patients in the analyzed studies with BMI greater
than the cutoff value. However, given that a lower baseline
BMI is a negative predictor of T2DM remission, we should
be cautious with the extrapolation of the benefits of surgery
to diabetic patients who have a relatively low BMI. This
finding highlights the importance of the implication of BMI
for patient selection and indications for surgery among Asian
patients.
Another issue regarding successful outcomes is whether
the use of insulin had an adverse effect on the remission rate of
T2DM. Because most patients requiring insulin therapy had a
longer known T2DM duration and greater preoperative
fasting glucose and HbA1c levels than those not requiring
insulin, insulin treatment may impact the severity of diabetes
to some degree. Compared with non-Asian patients, T2DM in
Asian patients is characterized by worse deterioration of early
phase insulin secretion, which appears to be associated with
severe impairment of β cell function. Specifically, patients
dependent on insulin therapy may have worse β cell function.
Thus, insulin independence may be a predictor of better
diabetes remission. Our meta-analysis further confirmed this.
Therefore, diabetes remission was more unpronounced in
patients requiring insulin therapy compared with prescribed
206 OBES SURG (2015) 25:199–208
oral hypoglycemic agents. These factors, although statistically
independent, are also interrelated. The lower rate of durable
remission in insulin-treated subjects is possibly related to a
lack of sufficient residual β cell mass. Diabetes duration is
known to reflect the residual β cell mass in T2DM patients,
both in morbidly and non-morbidly obese patients. Older age
is also associated with lower insulin sensitivity and dimin-
ished insulin secretion, and a high BMI is associated with
higher C-peptide levels [2]. At the same time, HbA1c levels
are an indicator of long-standing hyperglycemia, which has
been demonstrated to have direct glucotoxic effects on β cells
to reduce β cell secretory function [41]. Thus, HbA1c levels
are also related to decreased C-peptide levels. This combina-
tion of factors indicates that patients with higher C-peptide
levels are more likely to achieve remission. Of note in this
regard,β cell functionmay be a predictor of T2DM. Therefore,
it is possible that C-peptide levels are the most important
underlying clinical denominator for T2DM remission.
There were some limitations of this meta-analysis. First, our
review was limited by the studies using different criteria to
define T2DM remission. To address this issue, we repeated the
analysis by limiting our study to 13 articles that used diabetes
remission criteria equal to or stricter than the ADA criteria; we
still observed consistent results. Second, all the included stud-
ies were relatively short-term, with durations of 6 to 36months.
Third, a high degree of heterogeneity existed in most analyses.
Despite these shortcomings, our analysis of the included
studies suggested that an improved remission rate can be
expected in patients characterized by younger age, short dia-
betes duration, better glycemic control, and better β cell func-
tion. The results presented here shed new light on the impor-
tance of preoperative patient selection. Nonetheless, further
randomized studies to compare the reported data of predictive
factors using the ADA criteria to define T2DM remission with
adequate long-term follow-up among different populations are
warranted to establish appropriate selection criteria.
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